Sahil

Cancer stem cells (CSCs) represent a critical subpopulation driving tumor initiation, progression, metastasis, and therapeutic resistance. Their remarkable plasticity and ability to self-renew underlie cancer’s resilience and recurrence following conventional treatments. Recent advances in liquid biopsy technology have transformed cancer diagnostics by enabling the minimally invasive detection and dynamic monitoring of tumor-derived materials, including circulating tumor cells, cell-free nucleic acids, and exosomes. This review synthesizes the current landscape of CSC biomarkers, encompassing classical surface markers, epigenetic and metabolic signatures, and emerging multi-omic molecular profiles. We assess how these biomarkers are integrated into advanced liquid biopsy platforms, evaluating their diagnostic sensitivity and specificity as well as their clinical utility in tracking CSC dynamics throughout cancer progression and therapy. Technical challenges such as isolating rare CSC populations and distinguishing CSC-specific signals from normal stem cells are addressed, alongside developments in single-cell analysis, computational modeling, and multiplexed marker assays enhancing biomarker precision. Furthermore, we highlight the tumor microenvironment’s role in modulating CSC phenotypes and implications for biomarker reliability. By bridging foundational CSC biology with cutting-edge technologies in liquid biopsy, this review outlines translational strategies to better detect, characterize, and target CSCs, ultimately striving to improve outcomes by overcoming therapeutic resistance and reducing cancer relapse.

A respiratory disease of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. On 11 February 2020, WHO announced a name for the new coronavirus disease: COVID- 19. WHO is working 24 X 7 to provide advice, analyze data, coordinate with partners, help countries prepare, increase supplies and manage networks with experts. By 11 June 2020 - Current evidence suggests that most transmission occurs from symptomatic people through close contact with others very rapidly. Correspondingly, most of recommendations by WHO - on personal protective measures like use of masks and physical or social distancing are based on controlling transmission from symptomatic patients, including those with mild symptoms who are not easy to identify early. Comprehensive studies on transmission from asymptomatic patients are difficult to conduct, as they require testing of large population cohorts and more data are needed to better understand and quantify the transmissibility of SARS-CoV-2. During this global pandemic, the medical device regulatory environment is quickly adapting to meet the challenge of supplying sufficient PPE to front-line healthcare providers and life- saving equipment to those people in medical need. Manufacturers of medical device have to rise up to meet this challenge and embrace these opportunities to bring their device faster to the market and help us to take us out safely on the other side of the COVID-19 curve. One industry that is majorly impacted by this global crisis is the ventilator industry. There’s currently thought to be a global shortage of thousands of ventilators as the world attempts to tackle the deadly pandemic. During this pandemic health care systems are overwhelmed, and the effective delivery of medical care to all patients has become a challenge worldwide. Insufficient attention to early warning signs, inadequate stockpiling, lack of access to testing kits and personal protective equipment (PPE), and nationwide variability in the approaches to testing, distribution of PPE, and timing and degree of social distancing measures likely all affected the spread of the disease. Inadequate PPE, overcrowding, and difficulty protecting existing patients are key challenges to the medical industry.